Do analysts recommend BIOL or BBLG?

Given BIOLASE's higher probable upside, equities research analysts clearly believe BIOLASE is more favorable than Bone Biologics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BIOLASE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is BIOL or BBLG more profitable?

Bone Biologics has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. Bone Biologics' return on equity of -50.47% beat BIOLASE's return on equity. Company Net Margins Return on Equity Return on Assets BIOLASE -41.65% -1,782.73% -55.31% Bone Biologics N/A -50.47% -47.40%

Do analysts recommend BIOL or VBIO?

Given BIOLASE's higher possible upside, research analysts plainly believe BIOLASE is more favorable than Valion Bio, Inc. Common Stock. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BIOLASE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend BIOL or PTHL?

Given BIOLASE's higher probable upside, equities analysts plainly believe BIOLASE is more favorable than Pheton. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BIOLASE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Pheton 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, BIOL or PTHL?

Pheton has lower revenue, but higher earnings than BIOLASE. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BIOLASE $48.83M 0.00 -$20.63M -$14.94 N/A Pheton $305.22K 8.52 -$660K N/A N/A

Is BIOL or PTHL more profitable?

Pheton has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. Pheton's return on equity of 0.00% beat BIOLASE's return on equity. Company Net Margins Return on Equity Return on Assets BIOLASE -41.65% -1,782.73% -55.31% Pheton N/A N/A N/A

Which has preferable earnings and valuation, BIOL or SONX?

BIOLASE has higher revenue and earnings than Sonendo. Sonendo is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BIOLASE $48.83M 0.00 -$20.63M -$14.94 N/A Sonendo $44.40M 0.06 -$60.92M -$71.12 N/A

Is BIOL or SONX more profitable?

BIOLASE has a net margin of -41.65% compared to Sonendo's net margin of -92.74%. Sonendo's return on equity of -184.01% beat BIOLASE's return on equity. Company Net Margins Return on Equity Return on Assets BIOLASE -41.65% -1,782.73% -55.31% Sonendo -92.74% -184.01% -68.60%

Do analysts rate PFSA or BIOL?

Given BIOLASE's higher possible upside, analysts plainly believe BIOLASE is more favorable than Profusa. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Profusa 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BIOLASE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings and valuation, PFSA or BIOL?

BIOLASE has higher revenue and earnings than Profusa. Profusa is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Profusa $100K 11.59 -$35.82M -$169.72 N/A BIOLASE $48.83M 0.00 -$20.63M -$14.94 N/A

Is PFSA or BIOL more profitable?

Profusa has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. Profusa's return on equity of 0.00% beat BIOLASE's return on equity. Company Net Margins Return on Equity Return on Assets Profusa N/A N/A -1,348.07% BIOLASE -41.65% -1,782.73% -55.31%

BIOLASE (BIOL) Competitors

Compare

BIOL vs. BBLG, VBIO, PTHL, SONX, and PFSA

Should you buy BIOLASE stock or one of its competitors? MarketBeat compares BIOLASE with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BIOLASE include Bone Biologics (BBLG), Valion Bio, Inc. Common Stock (VBIO), Pheton (PTHL), Sonendo (SONX), and Profusa (PFSA). These companies are all part of the "medical equipment" industry.

How does BIOLASE compare to Bone Biologics?

BIOLASE (NASDAQ:BIOL) and Bone Biologics (NASDAQ:BBLG) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment.

In the previous week, Bone Biologics had 2 more articles in the media than BIOLASE. MarketBeat recorded 2 mentions for Bone Biologics and 0 mentions for BIOLASE. Bone Biologics' average media sentiment score of 0.43 beat BIOLASE's score of 0.00 indicating that Bone Biologics is being referred to more favorably in the news media.

Company	Overall Sentiment
BIOLASE	Neutral
Bone Biologics	Neutral

Bone Biologics has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. Bone Biologics' return on equity of -50.47% beat BIOLASE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BIOLASE	-41.65%	-1,782.73%	-55.31%
Bone Biologics	N/A	-50.47%	-47.40%

Bone Biologics has lower revenue, but higher earnings than BIOLASE. Bone Biologics is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A
Bone Biologics	N/A	N/A	-$3.11M	-$2.27	N/A

8.8% of BIOLASE shares are held by institutional investors. Comparatively, 34.3% of Bone Biologics shares are held by institutional investors. 0.3% of BIOLASE shares are held by company insiders. Comparatively, 6.1% of Bone Biologics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Given BIOLASE's higher probable upside, equities research analysts clearly believe BIOLASE is more favorable than Bone Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BIOLASE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BIOLASE has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, Bone Biologics has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market.

Summary

Bone Biologics beats BIOLASE on 11 of the 14 factors compared between the two stocks.

How does BIOLASE compare to Valion Bio, Inc. Common Stock?

BIOLASE (NASDAQ:BIOL) and Valion Bio, Inc. Common Stock (NASDAQ:VBIO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation and profitability.

8.8% of BIOLASE shares are held by institutional investors. Comparatively, 4.3% of Valion Bio, Inc. Common Stock shares are held by institutional investors. 0.3% of BIOLASE shares are held by insiders. Comparatively, 14.5% of Valion Bio, Inc. Common Stock shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Valion Bio, Inc. Common Stock had 1 more articles in the media than BIOLASE. MarketBeat recorded 1 mentions for Valion Bio, Inc. Common Stock and 0 mentions for BIOLASE. Valion Bio, Inc. Common Stock's average media sentiment score of 1.87 beat BIOLASE's score of 0.00 indicating that Valion Bio, Inc. Common Stock is being referred to more favorably in the news media.

Company	Overall Sentiment
BIOLASE	Neutral
Valion Bio, Inc. Common Stock	Very Positive

Valion Bio, Inc. Common Stock has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. Valion Bio, Inc. Common Stock's return on equity of -138.10% beat BIOLASE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BIOLASE	-41.65%	-1,782.73%	-55.31%
Valion Bio, Inc. Common Stock	N/A	-138.10%	-63.67%

Valion Bio, Inc. Common Stock has lower revenue, but higher earnings than BIOLASE. Valion Bio, Inc. Common Stock is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A
Valion Bio, Inc. Common Stock	$780K	3.27	-$8.88M	-$6.68	N/A

BIOLASE has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, Valion Bio, Inc. Common Stock has a beta of 1.79, meaning that its share price is 79% more volatile than the broader market.

Given BIOLASE's higher possible upside, research analysts plainly believe BIOLASE is more favorable than Valion Bio, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BIOLASE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Valion Bio, Inc. Common Stock beats BIOLASE on 9 of the 14 factors compared between the two stocks.

How does BIOLASE compare to Pheton?

BIOLASE (NASDAQ:BIOL) and Pheton (NASDAQ:PTHL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings and institutional ownership.

Pheton has lower revenue, but higher earnings than BIOLASE.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A
Pheton	$305.22K	8.52	-$660K	N/A	N/A

8.8% of BIOLASE shares are held by institutional investors. 0.3% of BIOLASE shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, BIOLASE's average media sentiment score of 0.00 equaled Pheton'saverage media sentiment score.

Company	Overall Sentiment
BIOLASE	Neutral
Pheton	Neutral

Given BIOLASE's higher probable upside, equities analysts plainly believe BIOLASE is more favorable than Pheton.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BIOLASE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Pheton	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BIOLASE has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market. Comparatively, Pheton has a beta of 5.4, indicating that its share price is 440% more volatile than the broader market.

Pheton has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. Pheton's return on equity of 0.00% beat BIOLASE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BIOLASE	-41.65%	-1,782.73%	-55.31%
Pheton	N/A	N/A	N/A

Summary

Pheton beats BIOLASE on 6 of the 10 factors compared between the two stocks.

How does BIOLASE compare to Sonendo?

BIOLASE (NASDAQ:BIOL) and Sonendo (NYSE:SONX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

In the previous week, BIOLASE's average media sentiment score of 0.00 equaled Sonendo'saverage media sentiment score.

Company	Overall Sentiment
BIOLASE	Neutral
Sonendo	Neutral

BIOLASE has a net margin of -41.65% compared to Sonendo's net margin of -92.74%. Sonendo's return on equity of -184.01% beat BIOLASE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BIOLASE	-41.65%	-1,782.73%	-55.31%
Sonendo	-92.74%	-184.01%	-68.60%

BIOLASE has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market. Comparatively, Sonendo has a beta of 2, meaning that its stock price is 100% more volatile than the broader market.

BIOLASE has higher revenue and earnings than Sonendo. Sonendo is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A
Sonendo	$44.40M	0.06	-$60.92M	-$71.12	N/A

8.8% of BIOLASE shares are held by institutional investors. Comparatively, 28.7% of Sonendo shares are held by institutional investors. 0.3% of BIOLASE shares are held by company insiders. Comparatively, 7.9% of Sonendo shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

BIOLASE beats Sonendo on 6 of the 10 factors compared between the two stocks.

How does BIOLASE compare to Profusa?

Profusa (NASDAQ:PFSA) and BIOLASE (NASDAQ:BIOL) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

Given BIOLASE's higher possible upside, analysts plainly believe BIOLASE is more favorable than Profusa.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profusa	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BIOLASE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

BIOLASE has higher revenue and earnings than Profusa. Profusa is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profusa	$100K	11.59	-$35.82M	-$169.72	N/A
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A

Profusa has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market. Comparatively, BIOLASE has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market.

In the previous week, Profusa had 3 more articles in the media than BIOLASE. MarketBeat recorded 3 mentions for Profusa and 0 mentions for BIOLASE. Profusa's average media sentiment score of 0.88 beat BIOLASE's score of 0.00 indicating that Profusa is being referred to more favorably in the media.

Company	Overall Sentiment
Profusa	Positive
BIOLASE	Neutral

9.8% of Profusa shares are held by institutional investors. Comparatively, 8.8% of BIOLASE shares are held by institutional investors. 0.8% of Profusa shares are held by insiders. Comparatively, 0.3% of BIOLASE shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profusa has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. Profusa's return on equity of 0.00% beat BIOLASE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Profusa	N/A	N/A	-1,348.07%
BIOLASE	-41.65%	-1,782.73%	-55.31%

Summary

Profusa and BIOLASE tied by winning 7 of the 14 factors compared between the two stocks.

Get BIOLASE News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIOL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BIOL vs. The Competition

Export

Metric	BIOLASE	Dental equipment & supplies Industry	Medical Sector	NASDAQ Exchange
Market Cap	$581K	$2.87M	$6.50B	$11.95B
Dividend Yield	N/A	N/A	2.67%	5.61%
P/E Ratio	0.00	N/A	24.65	23.63
Price / Sales	N/A	0.06	503.21	104.15
Price / Cash	N/A	N/A	43.05	54.72
Price / Book	N/A	0.01	10.43	6.70
Net Income	-$20.63M	-$60.92M	$3.56B	$337.26M

BIOLASE Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BIOL BIOLASE	N/A	N/A	N/A	N/A	$581K	$48.83M	N/A	160
BBLG Bone Biologics	0.8232 of 5 stars	$1.24 -2.3%	N/A	-77.7%	$2.23M	N/A	N/A	2	Short Interest Increase
VBIO Valion Bio, Inc. Common Stock	1.9427 of 5 stars	$0.65 -1.8%	N/A	-79.6%	$2.07M	N/A	N/A	10	Positive News Gap Down
PTHL Pheton	N/A	$0.28 -3.7%	N/A	-97.5%	$1.88M	$305.22K	N/A	11	Gap Down
SONX Sonendo	N/A	$0.33 flat	N/A	-45.5%	$1.58M	$44.40M	N/A	250

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BIOL) was last updated on 6/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BIOLASE (BIOL) Competitors

BIOL vs. BBLG, VBIO, PTHL, SONX, and PFSA

How does BIOLASE compare to Bone Biologics?

Summary

How does BIOLASE compare to Valion Bio, Inc. Common Stock?

Summary

How does BIOLASE compare to Pheton?

Summary

How does BIOLASE compare to Sonendo?

Summary

How does BIOLASE compare to Profusa?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIOL vs. The Competition

BIOLASE Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BIOLASE (BIOL) Competitors

BIOL vs. BBLG, VBIO, PTHL, SONX, and PFSA

How does BIOLASE compare to Bone Biologics?

Does the media refer more to BIOL or BBLG?

Is BIOL or BBLG more profitable?

Which has stronger earnings and valuation, BIOL or BBLG?

Do insiders & institutionals have more ownership in BIOL or BBLG?

Do analysts recommend BIOL or BBLG?

Which has more volatility and risk, BIOL or BBLG?

Summary

How does BIOLASE compare to Valion Bio, Inc. Common Stock?

Do institutionals and insiders have more ownership in BIOL or VBIO?

Does the media refer more to BIOL or VBIO?

Is BIOL or VBIO more profitable?

Which has better valuation and earnings, BIOL or VBIO?

Which has more volatility & risk, BIOL or VBIO?

Do analysts recommend BIOL or VBIO?

Summary

How does BIOLASE compare to Pheton?

Which has stronger valuation & earnings, BIOL or PTHL?

Do insiders and institutionals hold more shares of BIOL or PTHL?

Does the media favor BIOL or PTHL?

Do analysts recommend BIOL or PTHL?

Which has more risk and volatility, BIOL or PTHL?

Is BIOL or PTHL more profitable?

Summary

How does BIOLASE compare to Sonendo?

Does the media refer more to BIOL or SONX?

Is BIOL or SONX more profitable?

Which has more volatility & risk, BIOL or SONX?

Which has preferable earnings and valuation, BIOL or SONX?

Do institutionals and insiders have more ownership in BIOL or SONX?

Summary

How does BIOLASE compare to Profusa?

Do analysts rate PFSA or BIOL?

Which has preferable earnings and valuation, PFSA or BIOL?

Which has more risk and volatility, PFSA or BIOL?

Does the media refer more to PFSA or BIOL?

Do insiders & institutionals have more ownership in PFSA or BIOL?

Is PFSA or BIOL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIOL vs. The Competition

BIOLASE Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools